List of 3 Immunology Venture Capital investors in Europe [2022]

immunology venture capital

This article directly stems from the research process for our global venture capital investors database. Based on this list and our advanced keyword crawler technology, we created a list of venture capital investors that mention immunology-related keywords on their website. The list – offered as an Excel file – is perfectly suited to get in touch with the most relevant investors in the field.

Icons Thousandinvestors

This article highlights three significant immunology venture capital investment funds in Europe from our keyword crawler generated immunology venture capital investor list.

1. 4Bio Capital (UK)

4Bio Capital is a London-based VC firm that invests in projects in the life science sector. The company focuses on early-stage businesses that research advanced therapies that address unmet medical and social needs. Code Bio is part of their portfolio. The company with headquarters in Greater Philadelphia is developing non-viral gene therapies to treat genetic diseases.

2. BioMed Partners (Switzerland)

BioMed Partners is a well-known venture capital firm in Europe, who provide private equity and mezzanine financing to early- and mid-stage companies in the healthcare and life science sector. Allecra Therapeutics is part of their portfolio. They develop new treatments for multi drug-resistant bacterial infections. Another company is ImmunOs Therapeutics who develop human immunomodulatory proteins for cancer treatments.

3. Novalis (Belgium)

Novalis Biotech is a venture capital investor who is interested in early stage businesses in the life science sector. They focus on research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health. One portfolio company that focuses on immunology is Trince, a firm researching cell-based science. They are developing a transfection platform that can deliver effector molecules into any cell type. This is helpful in situations with hard-to-transfect cells like immune cells for cell therapies.

Picture Source:

Leave a Reply

Your email address will not be published. Required fields are marked *

Thousand Investors